Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgent Bio. Share News (RGT)

Share Price Information for Argent Bio. (RGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.00
Bid: 20.00
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 2.00 (10.00%)
Open: 21.00
High: 21.00
Low: 21.00
Prev. Close: 21.00
RGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: AEC Education, Treveria, ReGen...

Thu, 23rd Sep 2010 07:41

Asia-focused teaching group, AEC Education, have shown a strong progress in the half year to June 30, boasting a revenue increase of 169% to £8.64m (2009: £3.21m). This result is contributed heavily by the first full six month contribution from Malvern House (£4.12m), the London-based English language education provider, which was acquired in July 2009.Pre-tax profit was down from £403,000 in 2009, to £346,000 this year. This decrease was - as expected - due to the disruption to Malvern House's activities caused by the UK Border Agency's review of student visas. Earnings per share also dropped to 0.7p, from 1.3p the previous year.The half -yearly pre-tax profit of Treveria jumped to €193,000, significantly up from the loss of €176.8m made in the same period the previous year. Total cash balance held by Treveria plc and its subsidiaries stood at €100.4 million (31 December 2009: €128.3 million).Pharmaceutical company ReGen Therapeutics have seen a substantial reduction in pre-tax losses for the half year to June 30; narrowed to £242,000, down from £342,000 in 2009. Revenue from continuing operations amounted to £134,000, significantly up from £9,000 the previous year.First half operating losses of Immedia Group Plc rose to £100,375, compared to £40,615 recorded the previous year. Revenue fell to £1.72m, from £1.75 last year. Bruno Brookes, Chief Executive of Immedia, said that "the first half results reflect the difficult conditions prevailing in the UK and our results are similar to those for the first half of 2008. "Nevertheless the Company has continued to reduce its costs without loss of efficiencies or key personnel, whilst investing in developing its services and we look forward to the launch of a new service in the fourth quarter of 2010."Asian golfing tournament promoter Parallel Media shot a good first half score, boosting earnings before interest, tax, depreciation and amortisation to £0.47m from £0.39m in the first half of last year, despite revenue only edging up 2% to £5.8m from £5.7m.
More News
7 May 2024 14:21

Argent BioPharma shares begin trading on OTCQB Venture Market

(Alliance News) - Argent BioPharma Ltd on Tuesday celebrated the approval of its shares to trading in the US, and also announced the appointment of its new chief financial officer.

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Jul 2010 07:59

ReGen Therapeutics Buys Filtration Unit

LONDON (Dow Jones)--ReGen Therapeutics PLC (RGT.LN), a U.K. developer of healthcare products, said Thursday it has recently ordered a custom made filtration unit for use in the production of its nutraceutical product Colostrinin. MAIN FACTS: -Previously ReGen has hired this equipment, which

Read more
16 Jul 2010 07:12

ReGen Therapeutics Raises GBP70,000 Via Share Placing

LONDON (Dow Jones)--ReGen Therapeutics PLC(RGT.LN) said Friday it has conditionally placed 3.5 million new ordinary shares at 2 pence per ordinary share to raise GBP70,000 before expenses for general working capital purposes. MAIN FACTS: -The new ordinary shares will represent 4.99% of the e

Read more
7 Jul 2010 07:43

ReGen Therapeutics Confirms USV As Indian Colostrinin Distributor

LONDON (Dow Jones)--ReGen Therapeutics PLC (RGT.LN), a pharmaceutical company, Wednesday said USV Ltd has been appointed as the exclusive distributor of ReGen's nutritional supplement Colostrinin(TM) in India as announced in April. MAIN FACTS: -For commercial reasons the company had requeste

Read more
28 Jun 2010 11:38

ReGen Therapeutics Estimates 1H Revenue To Be GBP132,000

LONDON (Dow Jones)--ReGen Therapeutics Plc (RGT.LN) said Monday revenue for the first half of 2010 is estimated to be GBP132,000 compared with total revenues in 2009 of GBP56,055. MAIN FACTS: -This revenue has come from several of the markets where Colostrinin is now on sale and we look to c

Read more
25 Jun 2010 10:57

ReGen Therapeutics Raises GBP0.1M Via Issuance Of New Shares

LONDON (Dow Jones)--Biopharmaceutical company ReGen Therapeutics PLC (RGT.LN), said Friday it has conditionally placed 5 million new shares at 2 pence per share to raise GBP100,000, before expenses, for general working capital purposes. MAIN FACTS: -The new ordinary shares will represent 7.5

Read more
17 Jun 2010 07:41

ReGen Therapeutics Appoints ICUK To Assist China Developments

LONDON (Dow Jones)--ReGen Therapeutics PLC (RGT.LN), said Thursday that it has appointed Innovation China U.K. (ICUK) to assist in discussions with a major pharmaceutical company in China, which the company hopes will lead to the establishment of ReGen's business in this growing and important health

Read more
4 May 2010 12:03

Small caps round-up: ANT, Ariana Resources, Patagonia Gold...

Digital media software designer ANT gained ground after German set-top-box maker Kathrein-Werke licensed the ANT Galio Platform to target the Hybrid Broadcast Broadband TV (HbbTV) market. HbbTV, launched in August 2009, combines broadcast TV and broadband TV to provide enhanced digital TV services

Read more
9 Nov 2009 11:43

Small caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...

Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn

Read more
16 Jun 2009 16:12

ReGen sees no profit until 2010

Pharmaceutical company ReGen Therapeutics said it will not achieve sustainable profitability until 2010. Up until recently the group said it would reach profitability in the current year. "The credit crunch has had a severe impact on the business of our appointed and potential distributors and t

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.